BAY 1213790

Drug Profile

BAY 1213790

Alternative Names: BAY1213790; FXIa antibody

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare
  • Class Antibodies; Anticoagulants
  • Mechanism of Action Factor XIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Venous thromboembolism
  • No development reported Arterial thrombosis; Venous thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Arterial-thrombosis in Germany (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Venous-thrombosis in Germany (IV, Infusion)
  • 21 Sep 2017 Phase-II clinical trials in Venous thromboembolism (Prevention) in Greece, Czech Republic, Lithuania, South Africa (IV) (NCT03276143; EudraCT2016-002681-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top